

Grifols and Ace Alzheimer Center Barcelona renew their collaboration to promote the AMBAR[®] clinical program and incorporate new centers

- *The AMBAR[®] Center in Barcelona reinforces its position as a clinical reference and training center for the AMBAR Clinic centers recently opened in Madrid, Mallorca and Alicante (Spain), expanding access to the treatment for more patients*
- *The AMBAR (Alzheimer Management by Albumin Replacement) study has been shown to slow disease progression by 61% in patients with mild and moderate Alzheimer's disease¹*
- *Since the start of the project, more than 5,000 plasma exchanges with albumin have been performed, and the accumulated clinical experience supports the safety and potential of the protocol, which is included in the medical guidelines of the American Society for Apheresis (ASFA)²*

Barcelona, March 12, 2026 - Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the renewal of its agreement with Ace Alzheimer Center Barcelona to continue developing the AMBAR[®] (*Alzheimer Management by Albumin Replacement*) clinical program at the AMBAR Center in Barcelona. In addition, the company announced the opening of new AMBAR Clinic centers in Madrid, Mallorca and Alicante (Spain), reinforcing its commitment to expanding AMBAR and improving access to the protocol for more patients.

Through the agreement, the AMBAR Center—operational since 2021—strengthens its role as the reference and training hub for the new AMBAR Clinics. Grifols has recently reached agreements to open new centers that will apply the AMBAR protocol at HM Sanchinarro University Hospital in Madrid, at Juaneda Clinic in Palma de Mallorca, and at Quirónsalud Torrevieja Hospital in Alicante. In addition, Grupo Hospitalario HLA is expected to join the network soon. All these AMBAR Clinics will be integrated within hospital centers and connected through the AMBAR Network, a scientific network designed to promote cooperation among multidisciplinary teams, continuous protocol improvement, and clinical excellence.

The project will include the creation of an AMBAR registry with real world evidence (RWE) data, which will solidify clinical benefits and contribute further scientific knowledge. Grifols is also exploring options to incorporate clinics in other European countries such as Germany and the United Kingdom.

1. Boada M, López OL, Olazarán J et al. A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study. *Alzheimers Dement*. 2020 Oct;16(10):1412-1425. doi: [10.1002/alz.12137](https://doi.org/10.1002/alz.12137).

2. Connelly-Smith L, Alquist CR, Aqui NA et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. *J Clin Apher*. 2023 Apr;38(2):77-278. doi: [10.1002/jca.22043](https://doi.org/10.1002/jca.22043).

3. Boada M, Ramos-Fernández E, Guivernau B et al. Treatment of Alzheimer disease using combination therapy with plasma exchange and haemapheresis with albumin and intravenous immunoglobulin: Rationale and treatment approach of the AMBAR (Alzheimer Management By Albumin Replacement) study. *Neurologia*. 2016 Sep;31(7):473-81. English, Spanish. doi: [10.1016/j.nrl.2014.02.003](https://doi.org/10.1016/j.nrl.2014.02.003).

4. Boada M, Anaya F, Ortiz P et al. Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid- β Concentrations and Cognition Outcomes in Alzheimer's Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial. *J Alzheimers Dis*. 2017;56(1):129-143. doi: [10.3233/JAD-160565](https://doi.org/10.3233/JAD-160565)

The AMBAR clinical program is supported by 20 years of research and includes several international clinical trials^{1,3,4} that showed that periodic plasma exchange with albumin slowed disease progression by 61% in patients with mild and moderate Alzheimer's disease.¹

The clinical approach is based on the hypothesis that much of the beta-amyloid, one of the proteins that accumulates in the form of plaques in the brains of people with Alzheimer's disease, circulates in plasma, bound to albumin. By extracting this plasma, the displacement and removal of beta-amyloid would be promoted, which could help modify the progression of the disease and slow the patient's functional and cognitive decline.¹ In addition, patients may also benefit from the antioxidant and anti-inflammatory properties of albumin.

"Renewing the agreement with an organization like Ace Alzheimer Center allows us to continue advancing in a project that combines clinical expertise and collaboration to improve the approach to Alzheimer's disease. We want to consolidate a model that promotes clinical excellence and research, while facilitating access to the program in more centers interested in applying the AMBAR protocol to their patients," says Dr. Antonio Páez, medical director of Grifols' AMBAR clinical program. "The opening of new AMBAR Clinic centers in other Spanish cities is a decisive step in bringing this protocol to more people."

"This alliance reinforces our collaboration with Grifols, our commitment to innovation and to offering new therapeutic strategies that broaden the Alzheimer's treatment landscape. Strategies ranging from mild cognitive impairment to the most advanced stages of the disease," explains Dr. Mercè Boada, co-founder, neurologist and medical director of Ace Alzheimer Center Barcelona. "It is necessary to increase the knowledge of a multietiological disease that is going to need different approaches for its stabilization and improvement. The extensive experience acquired at the AMBAR Center is key to preparing the teams that will apply this treatment in the new clinics."

With this renewal, Grifols, Ace Alzheimer Center and the AMBAR Clinic centers share a social commitment to improving the quality of life and well-being of people with Alzheimer's and their families.

More than 5,000 plasma exchanges

Currently, the AMBAR Center in Barcelona applies this protocol to patients at different stages of the disease, with an average duration of 18 months. Both the application and follow-up are carried out by Ace Alzheimer Center's professional team of neurologists, intensivists, neuropsychologists and apheresis specialists, who have 30 years of experience in the management of neurodegenerative diseases.

Since its launch in 2004, the program has performed more than 5,000 plasma exchanges in Alzheimer's patients, consolidating the scientific evidence on the safety and potential of the protocol, which is included in the American Society for Apheresis (ASFA) medical guidelines.²

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across four main therapeutic areas: immunology, infectious diseases, pulmonology and critical care.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with close to 400 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 23,800 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the IBEX-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit www.grifols.com.

About Ace Alzheimer Center Barcelona, a pioneering model in the Alzheimer's world

Ace Alzheimer Center Barcelona, an innovative and benchmark organization in Spain, was founded in 1995 to meet the growing demand for the diagnosis and treatment of people with cognitive impairment and dementia, especially Alzheimer's disease.

It offers accurate diagnosis, multiple therapeutic strategies (such as plasmapheresis), personalized care and comprehensive support to patients and their families with a comprehensive care model that includes remote care, which ensures care and support to all people with Alzheimer's and their families from anywhere in the territory.

Diagnosis in early stages of dementia is a priority for Ace Alzheimer Center Barcelona, so it promotes free memory screenings, also online. Each year, its Diagnostic Unit serves about 9,000 people, of whom more than 4,000 suffer from dementia (3,000 of them, Alzheimer's type).

In addition, Ace Alzheimer Center Barcelona is considered one of the international benchmarks in research, especially clinical, neuropsychological, social and basic research. Its genetics and biomarkers team, recognized for its contribution to research, has the largest collection of genetic samples of Alzheimer's disease in Europe, which has allowed it to collaborate with the most important centers in the world.

Ace Alzheimer Center Barcelona's Clinical Trials Unit has participated in more than 170 clinical trials with worldwide participation aimed at all evolutionary stages of the disease, and they are one of the most important recruiting centers in the country.

MEDIA:

Grifols Press Office

Isana Navarro

isana.navarro@grifols.com

Tel: +34 670 920 476

INVESTORS:

Investor Relations and Sustainability

inversores@grifols.cominvestors@grifols.com

sostenibilidad@grifols.com – sustainability@grifols.com

Tel. +34 93 571 02 21

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are 'projections and future hypotheses'. Words and expressions such as 'believe', 'expect', 'anticipate', 'predict', 'hope', 'intend', 'should', 'will try to achieve', 'is estimated', 'future' and similar expressions, insofar as they refer to the Grifols group, are used to identify future projections and hypotheses. These expressions reflect the assumptions, hypotheses, expectations and predictions of the

management team at the time of writing this report, and these are subject to a series of factors that mean that the real results may be materially different. The future results of the Grifols group could be affected by events related to its own activities, such as shortages of supplies of raw materials for the manufacture of its products, the appearance on the market of competing products, or changes in the regulatory framework of the markets in which it operates, among others. At the date of preparation of this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. assumes no obligation to publicly report, revise or update the projections or future hypotheses to adapt them to facts or circumstances after the date of writing of this report, except when expressly required by applicable legislation. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Law 6/2023, of 17 March, on the Securities Markets and Investment Services, and any regulations implementing said legislation. Furthermore, this document does not constitute an offer to purchase, sell or exchange, or a solicitation of an offer to purchase, sell or exchange any securities, or a solicitation of any vote or approval in any other jurisdiction. The information contained in this document has not been verified or revised by the external auditors of the Grifols group.